Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

This study found that certain off-label topical therapies, including prostaglandin analogs and polyphenols, improved hair restoration in men with androgenetic alopecia over placebo in the short term, though long-term effects are unknown.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

This study observed that photobiomodulation therapy may contribute to hair growth stability or improvement in individuals with darker skin types, without reported adverse events, though its findings are limited by a small sample size.

This review provides a comprehensive look at injectable treatments like PRP, stem cells, and exosomes for hair regrowth, highlighting their potential to minimize systemic and localized side effects associated with conventional medications, and improve patient care by stimulating natural hair growth.

This article discusses pharmacologic treatments for male sexual offenders, focusing on reducing sexual drive through nonhormonal or hormonal means, but it reports no new clinical results.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study found that SULT1A1 enzyme activity, crucial for activating minoxidil, is significantly lower in eyebrow and eyelash follicles compared to scalp follicles, suggesting that additional sulfotransferase supplementation might enhance minoxidil-based hair growth treatments for these areas.

This review discusses the classification and diagnosis of primary cicatricial alopecias and reports no new clinical results; it highlights the need for effective treatments owing to limited evidence of current therapies' efficacy.

This review discusses the clinical challenges in treating alopecia areata with off-label therapies, highlighting the need to consider new research on JAK inhibitors, but reports no new clinical results.

This review discusses the off-label use of drugs and emphasizes the need for standardized guidelines due to varying international regulations and safety concerns, but reports no new clinical results.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study provides evidence-based recommendations for the off-label use of topical vitamin D in treating certain skin conditions, but highlights the need for higher quality studies for further validation.

This study discusses the role of physicians and pharmaceutical companies as entrepreneurial actors in off-label drug use, arguing they may advance patient care more quickly than regulatory agencies.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.

This review discusses the off-label uses of retinoids in dermatology, focusing on oral isotretinoin and acitretin, and reports no new clinical results.

This article reviews the literature on the off-label use of botulinum toxin for dermatological conditions, highlighting its potential effectiveness in treating rosacea, anal fissures, Raynaud phenomenon, hypertrophic scars, keloids, and hidradenitis suppurativa.

This review discusses the off-label use of drugs like Minoxidil, Aripripazole, and others, providing insights for physicians and pharmacists but reports no new clinical findings.

This study evaluated the molecular mechanisms, clinical efficacy, and safety of off-label therapies for male androgenetic alopecia and determined the relative efficacy of these therapies compared to topical minoxidil through a network meta-analysis.

This study found that oral spironolactone is generally well tolerated and may be effective for treating female-pattern hair loss, with improvements in hair regrowth stability as measured by Sinclair scores.

This report describes the case of identical twin males, where one applied topical 5% minoxidil for over a year on the beard and mustache area and the other did not, highlighting the anecdotal use of minoxidil for facial hair enhancement.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This review discusses the various off-label treatments for alopecia areata, highlighting that these therapies may promote hair growth but are not curative.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

This review reported that spironolactone, used off-label, is an effective and safe treatment option for adult women with acne, presenting fewer adverse reactions compared to common treatments like antimicrobials, which carry the risk of microbial resistance.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.